Résumé
Background: clara cell 10-kD protein (CC10), is an epithelial-derived pneumoprotein described in several chronic obstructive diseases. Its role as a predictive biomarker in severe asthma has not yet been explored. This study evaluates serum CC10 level variations during follow-up and the potential influence of the rs3741240 (G38A) CC10 gene polymorphism as predictors for outcomes in patients with moderate-to-severe asthma. Methods: within the French COBRA cohort, adults diagnosed with asthma were prospectively followed every 6 months. CC10 levels were measured at each visit, and CC10 gene polymorphism rs3741240 (G38A) was assessed. Demographic, clinical, biological (eosinophilia), lung function data and outcomes (frequency of asthma symptoms, ACQ, hospitalizations and exacerbations) were collected. Results: patients with severe asthma without any missing data over 5 consecutive visits (2.5 years, n=198) were included. Higher CC10 level at visit (n) was significantly associated with reduced reported asthma symptoms recorded at visit (n+1) (OR=0.914, 95% CI [0.838-0.997], p=0.043). However, CC10 levels failed to predict exacerbations, ACQ scores, hospitalizations, eosinophilia, or FEV1. Additionally, while the A/A genotype was consistently associated with lower CC10 levels over time, none of the CC10 polymorphisms (A/A, A/G et G/G) was associated with any asthma outcomes. Conclusion: circulating CC10 level during follow-up is inversely related to symptom burden but not with exacerbations in moderate-to-severe asthma patients, reducing its potential role as a predictive biomarker.